Morningstar
•
Aug 18, 2026
argenx SE: Argenx: Positive Vyvgart Data in Autoimmune Indication Supports Growth; FB102 Broadens Portfolio
Summary
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022,
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Alnylam Pharmaceuticals, Inc.
Sep 02, 2026
•
ALNY
KRYS: Raising target price to $400.00
Sep 02, 2026
•
KRYS
KRYS: Raising target price to $392.00
Aug 26, 2026
•
KRYS
Daily – Vickers Top Buyers & Sellers for 08/19/2026
Aug 19, 2026
•
CDNL, FIX, REZI, ASND, RSG, PH, AMD, CHEF, MOBI
KRYS: Raising target price to $366.00
Aug 19, 2026
•
KRYS
